Application of CRISPR/Cas9 Technology in Cancer Treatment: A Future Direction.

Gene editing, especially with clustered regularly interspaced short palindromic repeats associated protein 9 (CRISPR-Cas9), has advanced gene function science. Gene editing's rapid advancement has increased its medical/clinical value. Due to its great specificity and efficiency, CRISPR/Cas9 can accu...

Descripción completa

Detalles Bibliográficos
Publicado en:Current Oncology Vol. 30; no. 2; pp. 1954 - 1977
Autores principales: Rabaan, Ali A., AlSaihati, Hajir, Bukhamsin, Rehab, Bakhrebah, Muhammed A., Nassar, Majed S., Alsaleh, Abdulmonem A., Alhashem, Yousef N., Bukhamseen, Ammar Y., Al-Ruhimy, Khalil, Alotaibi, Mohammed, Alsubki, Roua A., Alahmed, Hejji E., Al-Abdulhadi, Saleh, Alhashem, Fatemah A., Alqatari, Ahlam A., Alsayyah, Ahmed, Farahat, Ramadan Abdelmoez, Abdulal, Rwaa H., Al-Ahmed, Ali H., Imran, Mohd.
Formato: Journal Article
Publicado: MDPI Feb2023
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=162118306&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 162118306
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        11980052
        5EKK
      jtl: Current Oncology
      issn: 11980052
      maglogo: N
    pubinfo:
      dt: Feb2023
      vid: 30
      iid: 2
      pid: 97109
      pub: MDPI
    artinfo:
      ui:
        162118306
        10.3390/curroncol30020152
        162118306
      ppf: 1954
      ppct: 23
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Application of CRISPR/Cas9 Technology in Cancer Treatment: A Future Direction.
      aug:
        au:
          Rabaan, Ali A.
          AlSaihati, Hajir
          Bukhamsin, Rehab
          Bakhrebah, Muhammed A.
          Nassar, Majed S.
          Alsaleh, Abdulmonem A.
          Alhashem, Yousef N.
          Bukhamseen, Ammar Y.
          Al-Ruhimy, Khalil
          Alotaibi, Mohammed
          Alsubki, Roua A.
          Alahmed, Hejji E.
          Al-Abdulhadi, Saleh
          Alhashem, Fatemah A.
          Alqatari, Ahlam A.
          Alsayyah, Ahmed
          Farahat, Ramadan Abdelmoez
          Abdulal, Rwaa H.
          Al-Ahmed, Ali H.
          Imran, Mohd.
        affil: Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311, Saudi Arabia
      sug:
      ab: Gene editing, especially with clustered regularly interspaced short palindromic repeats associated protein 9 (CRISPR-Cas9), has advanced gene function science. Gene editing's rapid advancement has increased its medical/clinical value. Due to its great specificity and efficiency, CRISPR/Cas9 can accurately and swiftly screen the whole genome. This simplifies disease-specific gene therapy. To study tumor origins, development, and metastasis, CRISPR/Cas9 can change genomes. In recent years, tumor treatment research has increasingly employed this method. CRISPR/Cas9 can treat cancer by removing genes or correcting mutations. Numerous preliminary tumor treatment studies have been conducted in relevant fields. CRISPR/Cas9 may treat gene-level tumors. CRISPR/Cas9-based personalized and targeted medicines may shape tumor treatment. This review examines CRISPR/Cas9 for tumor therapy research, which will be helpful in providing references for future studies on the pathogenesis of malignancy and its treatment.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N